1. Signaling Pathways
  2. Epigenetics
    JAK/STAT Signaling
    Stem Cell/Wnt
  3. JAK
  4. JAK2 Inhibitors

JAK2 Inhibitors

JAK1

JAK2

JAK3

Tyk2

JAK

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform JAK2 together.

Please try each isoform separately.

JAK2 Specific Inhibitors
Product Name JAK2 JAK1 JAK3 Tyk2 JAK2 Selectivity Purity
JAK2-IN-7
JAK2, IC50: 3 nM
JAK1, IC50: 42 nM
JAK3, IC50: 94 nM
Tyk2, IC50: 75 nM
Selective Inhibitor
Fedratinib
JAK2, IC50: 3 nM
JAK2(V617F), IC50: 3 nM
      Selective Inhibitor ≥98.0%
WP1066
JAK2
      Selective Inhibitor 99.90%
Zotiraciclib
JAK2, IC50: 73 nM
      Selective Inhibitor 99.96%
Gandotinib
JAK2, IC50: 3 nM
 
JAK3, IC50: 48 nM
Tyk2, IC50: 44 nM
Selective Inhibitor 99.96%
Lestaurtinib
JAK2, IC50: 0.9 nM
      Selective Inhibitor ≥99.0%
CHZ868
JAK2, IC50: 110 nM
      Selective Inhibitor 99.22%
BMS-911543
JAK2, IC50: 1.1 nM
JAK1, IC50: 75 nM
JAK3, IC50: 360 nM
Tyk2, IC50: 66 nM
Selective Inhibitor 97.80%
Cucurbitacin I
JAK2
      Selective Inhibitor ≥98.0%
CEP-33779
JAK2, IC50: 1.8 nM
 
JAK3, IC50: 150 nM
  Selective Inhibitor 99.36%
TG101209
JAK2, IC50: 6 nM
 
JAK3, IC50: 169 nM
  Selective Inhibitor 99.72%
Ilginatinib
JAK2, IC50: 0.72 nM
JAK1, IC50: 33 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
Selective Inhibitor 99.15%
XL019
JAK2, IC50: 2.2 nM
 
JAK3, IC50: 214.2 nM
  Selective Inhibitor ≥98.0%
Fedratinib hydrochloride hydrate
JAK2, IC50: 3 nM
JAK2(V617F), IC50: 3 nM
      Selective Inhibitor 99.82%
NVP-BSK805 dihydrochloride
JAK2 JH1, IC50: 0.48 nM
FL JAK2 V617F, IC50: 0.56 nM
FL JAK2 wt, IC50: 0.58 nM
JAK1 JH1, IC50: 31.63 nM
JAK3 JH1, IC50: 18.68 nM
TYK2 JH1, IC50: 10.76 nM
Selective Inhibitor ≥98.0%
NSC 42834
JAK2-WT, IC50: 15 μM
JAK2-V617F, IC50: 28 μM
      Selective Inhibitor 96.79%
Ilginatinib hydrochloride
JAK2, IC50: 0.72 nM
JAK1, IC50: 33 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
Selective Inhibitor 98.02%
Ilginatinib maleate
JAK2, IC50: 0.72 nM
JAK1, IC50: 33 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
Selective Inhibitor 97.04%
JAK2-IN-6
JAK2, IC50: 22.86 μg/mL
      Selective Inhibitor
G5-7
JAK2
      Selective Inhibitor 99.84%
Ruxolitinib
JAK2, IC50: 2.8 nM
JAK1, IC50: 3.3 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
Pan Inhibitor 99.99%
Tofacitinib
JAK2, IC50: 20 nM
JAK1, IC50: 112 nM
JAK3, IC50: 1 nM
  Pan Inhibitor 99.96%
Baricitinib
JAK2, IC50: 5.7 nM
JAK1, IC50: 5.9 nM
JAK3, IC50: 560 nM
Tyk2, IC50: 53 nM
Pan Inhibitor ≥95.0%
JAK2/FLT3-IN-1
JAK2, IC50: 0.7 nM
JAK1, IC50: 26 nM
JAK3, IC50: 39 nM
  Pan Inhibitor
Upadacitinib
JAK2, IC50: 0.2 μM
JAK1, IC50: 0.043 μM
JAK3, IC50: 2.3 μM
Tyk2, IC50: 4.7 μM
Pan Inhibitor 99.96%
Ruxolitinib phosphate
JAK2, IC50: 2.8 nM
JAK1, IC50: 3.3 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
Pan Inhibitor ≥98.0%
Tofacitinib citrate
JAK2, IC50: 20 nM
JAK1, IC50: 112 nM
JAK3, IC50: 1 nM
  Pan Inhibitor 99.98%
Filgotinib
JAK2, IC50: 28 nM
JAK1, IC50: 10 nM
JAK3, IC50: 810 nM
Tyk2, IC50: 116 nM
Pan Inhibitor 99.83%
Peficitinib
JAK2, IC50: 5 nM
JAK1, IC50: 3.9 nM
JAK3, IC50: 0.7 nM
Tyk2, IC50: 4.8 nM
Pan Inhibitor 99.78%
Pacritinib
JAK2V617F, IC50: 19 nM
JAK2wt, IC50: 23 nM
JAK1, IC50: 1280 nM
JAK3, IC50: 520 nM
Tyk2, IC50: 50 nM
Pan Inhibitor 99.93%
Momelotinib
JAK2, IC50: 18 nM
JAK1, IC50: 11 nM
JAK3, IC50: 155 nM
  Pan Inhibitor 98.93%
Delgocitinib
JAK2, IC50: 2.6 nM
JAK1, IC50: 2.8 nM
JAK3, IC50: 13 nM
Tyk2, IC50: 58 nM
Pan Inhibitor 99.76%
Abrocitinib
JAK2, IC50: 803 nM
JAK1, IC50: 29 nM
 
Tyk2, IC50: 1253 nM
Pan Inhibitor 99.79%
AZD-1480
JAK2, IC50: <0.4 nM
JAK1, IC50: 1.3 nM
    Pan Inhibitor 99.37%
AT9283
JAK2, IC50: 1.2 nM
 
JAK3, IC50: 1.1 nM
  Pan Inhibitor 99.61%
PF-06700841 P-Tosylate
JAK2, IC50: 77 nM
JAK1, IC50: 17 nM
JAK3, IC50: 6.9 μM
  Pan Inhibitor 99.66%
Oclacitinib maleate
JAK2, IC50: 18 nM
JAK1, IC50: 10 nM
JAK3, IC50: 99 nM
Tyk2, IC50: 84 nM
Pan Inhibitor 99.65%
Cerdulatinib
JAK2, IC50: 6 nM
JAK1, IC50: 12 nM
JAK3, IC50: 8 nM
Tyk2, IC50: 0.5 nM
Pan Inhibitor 99.0%
Pyridone 6
JAK2, IC50: 1 nM
Murine JAK1, IC50: 15 nM
JAK3, IC50: 5 nM
Tyk2, IC50: 1 nM
Pan Inhibitor 98.04%
Baricitinib phosphate
JAK2, IC50: 5.7 nM
JAK1, IC50: 5.9 nM
JAK3, IC50: 560 nM
Tyk2, IC50: 53 nM
Pan Inhibitor 99.91%
SAR-20347
JAK2, IC50: 26 nM
JAK1, IC50: 23 nM
JAK3, IC50: 41 nM
Tyk2, IC50: 0.6 nM
Pan Inhibitor 98.04%
AZ960
JAK2, Ki: 0.45 nM
JAK2, IC50: <3 nM
 
JAK3, IC50: 9 nM
  Pan Inhibitor ≥98.0%
JAK/HDAC-IN-1
JAK2, IC50: 4 nM
JAK1, IC50: 4.8 nM
JAK3, IC50: 7.4 nM
Tyk2, IC50: 49 nM
Pan Inhibitor 98.04%
Decernotinib
JAK2, Ki: 13 nM
JAK1, Ki: 11 nM
JAK3, Ki: 2.5 nM
Tyk2, Ki: 11 nM
Pan Inhibitor 99.45%
JAK3-IN-1
JAK2, IC50: 1050 nM
JAK1, IC50: 896 nM
JAK3, IC50: 4.8 nM
  Pan Inhibitor 99.98%
PF-06263276
JAK2, IC50: 23.1 nM
JAK1, IC50: 2.2 nM
JAK3, IC50: 59.9 nM
Tyk2, IC50: 29.7 nM
Pan Inhibitor ≥99.0%
SC99
JAK2
      Pan Inhibitor 99.07%
SHR0302
JAK2
JAK1
JAK3
Tyk2
Pan Inhibitor 99.58%
Reticuline
JAK2
      Pan Inhibitor 98.11%
Momelotinib sulfate
JAK2, IC50: 18 nM
JAK1, IC50: 11 nM
JAK3, IC50: 155 nM
  Pan Inhibitor ≥95.0%
Tyk2-IN-9
JAK2, IC50: 8 nM
JAK1, IC50: 21 nM
 
Tyk2, IC50: 6 nM
Pan Inhibitor 99.62%
Cerdulatinib hydrochloride
JAK2, IC50: 6 nM
JAK1, IC50: 12 nM
JAK3, IC50: 8 nM
Tyk2, IC50: 0.5 nM
Pan Inhibitor 99.54%
PF-06700841
JAK2, IC50: 77 nM
JAK1, IC50: 17 nM
JAK3, IC50: 6.9 μM
  Pan Inhibitor
Protosappanin A
JAK2
      Pan 98.88%
TCS 21311
JAK2, IC50: 2.55 μM
JAK1, IC50: 1.017 μM
JAK3, IC50: 8 nM
  Pan Inhibitor ≥98.0%
JAK1-IN-4
JAK2, IC50: 12.8 μM
JAK1, IC50: 85 nM
    Pan Inhibitor
JAK-IN-3
JAK2, IC50: 70 nM
JAK1, IC50: 5 nM
JAK3, IC50: 3 nM
Tyk2, IC50: 34 nM
Pan Inhibitor
JAK-2/3-IN-1
JAK2, Ki: <250 nM
 
JAK3, Ki: <250 nM
  Pan Inhibitor
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
JAK2, Ki: 0.7 nM
JAK1, Ki: 0.7 nM
JAK3, Ki: 0.4 nM
Tyk2, Ki: 4.8 nM
Pan Inhibitor
NSC 33994
JAK2, IC50: 60 nM (JAK2 Val617Phe kinase activity )
      Pan Inhibitor